TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The Heart Failure Society of America’s HF STATS 2026 report projects that the number of U.S. adults with heart failure will rise from 7.7 million to 11.4 million by 2050. It also reports increasing mortality and low use of four recommended medicines among patients with reduced ejection fraction, while calling for better prevention and delivery of proven care.
The Heart Failure Society of America’s HF STATS 2026 report projects that 11.4 million U.S. adults will have heart failure by 2050, up from an estimated 7.7 million now. The report also records rising mortality and low use of recommended medicines, describing a growing public health challenge even as treatments have improved.
The report estimates that heart failure affects 3% of U.S. adults, or 7.7 million people. It projects prevalence of 3.2%, or 8.7 million people, by 2030; 3.6%, or 10.3 million, by 2040; and 3.8%, or 11.4 million, by 2050. The authors attribute the projected rise in part to an aging population and increasing rates of obesity, hypertension and other cardiometabolic risk factors.
Mortality trends are also moving upward. Age-adjusted heart failure mortality increased about 37% from 2010 to 2023, according to the report, reversing more than a decade of earlier progress. In separate figures covering 2001 to 2020, unadjusted mortality among adults ages 25 to 44 rose from 0.6 to 1.4 deaths per 100,000; among those ages 45 to 64, it rose from 6.4 to 12.5 per 100,000. Those age-specific figures use unadjusted rates and should not be conflated with the age-adjusted national trend.
The report says just 18% of more than 3 million patients with heart failure with reduced ejection fraction receive all four pillars of guideline-directed medical therapy in real-world care. The therapies named are beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists and SGLT2 inhibitors. The report describes these treatments as beneficial and relatively low-cost, but says they remain underused.
Rising Deaths and Treatment Gaps
The projections matter because they point to a larger population needing diagnosis, ongoing treatment and health services over coming decades. The mortality figures add a present-day concern: the increase spans years in which medical options have expanded, yet population-level outcomes have worsened. The report does not establish a single cause for that change, but identifies prevention, early recognition and access to established care as areas requiring attention.
The treatment gap may also represent a practical opportunity. In an accompanying editorial, Yale School of Medicine physicians Thiru Chinnadurai and Tariq Ahmad argue that better initiation, dose adjustment and continuation of recommended medicines could help more patients receive therapies supported by evidence. They suggest electronic health record decision support, multidisciplinary programs and simpler medication regimens as possible implementation approaches. These are proposed strategies; the report does not quantify how much any one measure would reduce deaths or future prevalence.
Age patterns add another reason for early action. Heart failure prevalence remains relatively low among younger adults, but the report says hospitalization rates are declining among adults 65 and older while rising among younger people. The authors and editorialists call for more attention to risk factors and earlier stages of disease, alongside efforts to address racial and geographic disparities in care and shortages in advanced heart failure specialists.
As an affiliate, we earn on qualifying purchases.
How the Report Frames the Trend
HF STATS is the Heart Failure Society of America’s annual report on heart failure data and trends. Its 2026 edition was published in the Journal of Cardiac Failure. The estimates combine several kinds of measures: projected prevalence, age-adjusted mortality over 2010–2023, and unadjusted age-specific mortality over 2001–2020. Each describes a different aspect of the burden, so the figures do not all cover the same period or use the same adjustment method.
The report estimates that about one in four Americans may develop heart failure during their lifetime. It also gives current prevalence estimates among adults ages 20 to 39 of 0.1% for men and 0.2% for women, and among ages 40 to 59 of 2.2% for men and 1.8% for women. The authors connect future growth to population aging and cardiometabolic risks, while highlighting that younger adults should not be overlooked because of the rising hospitalization and mortality patterns reported for some younger age groups.
“HF STATS 2026 reports a condition at a critical inflection point: rising mortality, younger age at onset, an expanding at-risk population, and widening gaps between evidence and practice.”
— HF STATS 2026 authors, chaired by Eiran Gorodeski
blood pressure monitor for seniors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Data Cannot Yet Show
The projections describe expected prevalence under the report’s assumptions; they do not establish exactly how many people will develop heart failure in each future year. The source material does not provide the full projection methods or a range of uncertainty for those estimates. It also does not identify a single explanation for rising mortality or establish how much underuse of medication contributes to that trend.
The report cites real-world data showing that 18% of patients with reduced ejection fraction receive all four medication classes, but the supplied material does not specify the data collection period or explain how treatment use varies by location, race, insurance status or clinical circumstances. It also does not quantify the effects of the proposed care-delivery programs. Those details would help assess where gaps are widest and which interventions might have the greatest impact.
As an affiliate, we earn on qualifying purchases.
Turning Recommendations Into Care
The report’s authors call for coordinated action across clinical specialties, health systems, payers, policymakers and communities. The accompanying editorials point to practical areas for further work: earlier risk screening, attention to stage B heart failure, stronger use of risk assessment and natriuretic peptide testing where appropriate, and systems that help clinicians start and sustain recommended treatment.
The report does not announce a specific policy, implementation timetable or next data release. The next measurable developments will be whether health systems expand prevention and treatment programs and whether future reports show changes in medication use, hospitalization patterns and mortality. The authors say reversing the trends will require a broad commitment, while the scale and timing of any improvement remain unknown.
medication management for heart failure
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How many U.S. adults are projected to have heart failure by 2050?
The HF STATS 2026 report projects 11.4 million U.S. adults, or 3.8% of adults, by 2050, compared with an estimated 7.7 million now.
What mortality increase does the report describe?
It reports that age-adjusted heart failure mortality rose about 37% from 2010 to 2023. Separate unadjusted figures show mortality increasing among adults ages 25 to 44 and 45 to 64 from 2001 to 2020.
What does the report say about heart failure treatment?
According to the report’s real-world data, 18% of more than 3 million patients with reduced ejection fraction receive all four named pillars of guideline-directed medical therapy.
Why does the report focus on younger adults?
Although heart failure prevalence is lower among younger adults, the report says hospitalization rates are rising in younger groups and mortality increased among adults ages 25 to 64 over the 2001–2020 period it examined.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
